Fibroblast Activation Protein alpha (FAP)

Overview

FAP, or fibroblast activation protein alpha, is a cell-surface serine protease that is widely studied in cancer biology and tumor microenvironment research. It is of particular interest because of its association with activated fibroblasts and other stromal compartments in tumors, where it can serve as a biomarker and a therapeutic target. In biomedical research, FAP is often discussed in the context of tumor stroma remodeling, immune exclusion, and targeted delivery strategies.

As a protein target, FAP is notable for its expression pattern in certain malignancies and tumor-associated non-malignant cells, which can make it attractive for selective targeting approaches. In recent translational studies, FAP has been investigated as a target for engineered cell therapies, including chimeric antigen receptor T cells, with the goal of improving antitumor activity while exploiting its tumor-associated expression profile.

Recent Publications Summary

Recent research has established FAP as a versatile target for cellular immunotherapy approaches. Numerous studies have developed strategies for in vivo CAR-T and CAR-macrophage (CAR-M) generation targeting FAP. Polymer-lipid nanoparticles (ERTLNPs) modified with p-toluenesulfonyl arginine were used to deliver mRNA encoding FAP-targeted CAR T cells systemically, achieving efficient T cell transfection and activation in the spleen without exogenous stimulation 42587055Aug. Similarly, CD163 antibody-conjugated liposomal nanoparticles encapsulating FAP-specific CAR-M mRNA successfully transduced liver macrophages and generated functional FAP-targeting CAR-modified macrophages, resulting in reduced extracellular matrix and enhanced resolution of liver fibrosis 42213756May. A cell-free approach using CAR-exosomes derived from FAP-targeting CAR-T cells demonstrated efficacy in treating intrauterine adhesion by inhibiting fibrosis and promoting endometrial regeneration while avoiding the cytokine-release toxicity associated with direct CAR-T cell administration 42060824Apr. Additionally, non-viral CRISPR/Cas9-based genetic engineering was used to generate CISH-knockout FAP-targeting CAR-T cells for glioblastoma therapy, which exhibited robust proliferation and potent antitumor efficacy 41930329Apr.

FAP-targeted imaging has emerged as a critical diagnostic tool, with multiple radiotracer platforms demonstrating superior tumor visualization compared to conventional approaches. Heterodimeric radioligands combining FAP and CAIX targeting showed high binding affinity for FAP and significantly enhanced tumor uptake and retention over monomeric tracers 42367011Jun. Glycosylated and dimeric FAP-targeted radiotracers exhibited markedly higher tumor uptake (9.5 ± 1.75% ID/g) in glioblastoma models compared to monomeric variants 42343548Jun. A novel 18F-labeled FAPI tracer ([18F]AlF-AA-FAPT) demonstrated superior pharmacokinetic properties, higher tumor-specific uptake, and lower background accumulation in nontarget organs, with pilot clinical imaging showing enhanced efficacy for both primary and metastatic lesions 42062218Apr. Polyvalency engineering strategies, such as the trimerized [68Ga]Ga-TRAP-(FAPI)3 tracer, achieved a 33-fold enhancement in cellular uptake and 7.39-fold higher tumor accumulation compared to monomeric [68Ga]Ga-FAPI-04 41946434Apr. PEG-modified dimeric FAP radiotracers demonstrated pronounced dependence on PEG linker length, with optimized variants achieving superior tumor uptake and prolonged retention 41887115Mar. Clinical evaluation of [68Ga]Ga-FAPI-46 PET/CT for preoperative assessment of peritoneal carcinomatosis showed promise for accurate disease mapping 42167805May.

Therapeutic targeting of FAP has yielded clinical and preclinical evidence of efficacy across multiple modalities. A small-molecule-drug conjugate (OncoFAP glidotin) targeting FAP displayed an excellent safety profile in a dose-escalation trial in dogs with spontaneous FAP-positive tumors, with 75% response rate and tumor volume reductions up to 88% after four weeks of treatment 42142054May. Radiopharmaceutical therapy with [177Lu]Lu-RTX-2358 was tolerable with manageable dosimetry to critical organs, achieving disease stabilization in multiple patients with advanced FAP-expressing solid tumors 41786480Mar. Beyond direct targeting, a FAP-targeted lymphotoxin β receptor (LTBR) agonist was engineered to remodel the tumor microenvironment by driving high endothelial venule differentiation and promoting tertiary lymphoid structure formation, thereby enhancing immune cell infiltration and potentiating checkpoint inhibitor response 42012453Apr. Studies of the tumor microenvironment revealed that FAP-expressing cancer-associated fibroblasts constitute functionally distinct subpopulations; in triple-negative breast cancer, a myofibroblastic-inflammatory CAF subset (my_iCAFs) co-expressing FAP and inflammatory markers was significantly enriched and associated with elevated PI3K/AKT and pro-inflammatory TNF/NF-κB signaling 42436124Jul. In oral squamous cell carcinoma, FAP-expressing fibroblasts orchestrate immunosuppression through WNT2-mediated reprogramming of C1QC+ macrophages, and FAP inhibition reduced C1QC+ macrophage infiltration and reshaped the immune landscape 41831519Mar.

FAP has also emerged as a therapeutic target in non-malignant fibrotic and inflammatory diseases. Elevated FAP expression was documented in patients with metabolic dysfunction-associated steatotic liver disease (MASLD), where FAP functions as a serine protease regulating proteolytic processing of circulating substrates including fibroblast growth factor 21 and α2-antiplasmin 42233208Jun. Pharmacological FAP inhibition effectively mitigated aging-related periodontitis by suppressing nuclear factor kappa-B signaling in senescent gingival fibroblasts, reducing osteoclast differentiation and preserving alveolar bone integrity 41966776Apr. FAP expression has also been proposed as an early biomarker for chronic lung allograft dysfunction, the leading cause of late graft failure after lung transplantation 41412718Dec.

What Changes, What Holds

1. In vivo FAP-targeted cell therapies reach fibrotic disease
NEW DIRECTION CAR-macrophage and CAR-exosome platforms targeting FAP demonstrate in vivo efficacy in liver fibrosis and intrauterine adhesion 42213756May42060824Apr, extending therapeutic applications beyond the tumor context established in the baseline. The Overview confines FAP to cancer immunotherapy; these results reveal FAP-expressing fibroblasts as drivers of pathological fibrosis amenable to engineered cell targeting in non-malignant settings, substantially widening the indication space.

2. FAP-targeted radiotracers achieve superior tumor uptake and clinical translation
NEW DIRECTION Polyvalency engineering of FAP radiotracers—trimerized and dimeric variants—delivers dramatic enhancements in cellular uptake and tumor accumulation, with clinical imaging demonstrating efficacy in disease mapping 41946434Apr42167805May. The Overview does not specify imaging as a FAP application; these results establish molecular imaging as a distinct clinical modality, opening diagnostics as a primary rationale for FAP-directed development alongside therapeutic targeting.

3. FAP-targeted therapeutics confirm efficacy across modalities and illuminate CAF biology
REINFORCES Small-molecule drug conjugate and radiopharmaceutical approaches targeting FAP achieve antitumor responses in preclinical and clinical settings 42142054May, validating FAP as a therapeutic target. Mechanistic studies reveal that FAP-expressing fibroblasts orchestrate immunosuppression through WNT2-mediated macrophage reprogramming 41831519Mar, elaborating on the immune-exclusion mechanism the Overview identifies without fully characterizing.

4. FAP emerges as a pathogenic driver in non-malignant fibrotic and metabolic disease
NEW DIRECTION Elevated FAP expression associates with metabolic dysfunction-associated steatotic liver disease and chronic lung allograft dysfunction, while FAP inhibition mitigates aging-related periodontitis by suppressing senescent fibroblast signaling 42233208Jun41966776Apr. The Overview restricts FAP to cancer biology and tumor stroma; these results reveal FAP as a therapeutic and diagnostic target in non-malignant fibrosis and metabolic disease, substantially expanding the relevance of FAP beyond the tumor context.

Overview update candidates: FAP-targeted molecular imaging; in vivo engineered cell therapies for non-malignant fibrotic disease; FAP in metabolic and age-related fibrotic disease; CAF subpopulation biology in immune exclusion.